Hindustan Bio Sciences (BOM:532041) Change In Working Capital : ₹0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Hindustan Bio Sciences Change In Working Capital?

Hindustan Bio Sciences's change in working capital for the quarter that ended in Sep. 2024 was ₹0.00 Mil.

Hindustan Bio Sciences's change in working capital for the fiscal year that ended in Mar. 2024 was ₹-14.69 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Hindustan Bio Sciences Change In Working Capital Historical Data

The historical data trend for Hindustan Bio Sciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hindustan Bio Sciences Change In Working Capital Chart

Hindustan Bio Sciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Working Capital

Get a 7-Day Free Trial

7.12

16.54

-0.59

-0.18

-14.69

Hindustan Bio Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Hindustan Bio Sciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Hindustan Bio Sciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Hindustan Bio Sciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hindustan Bio Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hindustan Bio Sciences Ltd (BOM:532041) » Definitions » Change In Working Capital

Traded in Other Exchanges

N/A

Address

Road No. 2, Banjara Hills, H.No. 8-2-269/S, Plot No. 31, Sagar Co-Operative Housing Society, Hyderabad, TG, IND, 500034

Website

https://www.hindustanbiosciences.in

Hindustan Bio Sciences Ltd is an India-based company operating in the pharmaceutical and biotechnology sector. It is engaged in the trading of Drugs and Medicines. The company markets a nephrology product, Recombinant Human Erythropoietin, which is useful for the treatment of anemia associated with chronic renal failure. In addition, the firm also manufactures and markets pharmaceutical products in different forms such as tablets, capsules, drops, externals, and syrups. Its other formulations comprise Pantorest, Maxion, Edinil, Aromycin, Livohin, and others. Geographically, the group sells its products within India and also exports it to other countries.

Hindustan Bio Sciences Headlines

No Headlines